Skip to main content
SpringerLink
Log in

Hormonal Therapy of the Infertile Man

  • Chapter
Endocrine Replacement Therapy in Clinical Practice

Part of the book series: Contemporary Endocrinology ((COE))

  • 121 Accesses

Abstract

About 10% of couples seek infertility assessment when pregnancy does not occur within a year (1). Among these infertile couples, male factors are primarily responsible for 20–25% and contribute to another 30% of cases; no male or female factor can be identified in approx 15% (2,3). Despite over half of all infertile couples having a male factor contributing to their infertility, most have oligo/asthenozoospermia without a specific diagnosis (“idiopathic”) so that neither cure nor even logical treatment is possible. Indeed, for male infertility, specific treatment, defined as rational medical treatment aim at rectifying a verifiable and sufficient cause, is effectively limited to hormonal treatment of gonadotropin deficiency.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Snick HK, Snick TS, Evers JL, Collins JA. The spontaneous pregnancy prognosis in untreated subfertile couples: the Walcheren primary care study. Hum Reprod 1997; 12: 1582–1588.

    Article  PubMed  CAS  Google Scholar 

  2. Comhaire FH, de Krester DM, Farley TM, Rowe PJ. Towards more objectivity in diagnosis and management of male fertility. Int J Androl 1987: 1–53.

    Google Scholar 

  3. Nieschlag E. Classification of andrological disorders. In: Nieschlag E, Behre HM, eds. Andrology: Male Reproductive Health and Dysfunction, vol. 1. Springer, Berlin, 2000.

    Google Scholar 

  4. Collins JA, Burrows EA, Wilan AR. The prognosis for live birth among untreated infertile couples. Fertil Steril 1995; 64: 22–28.

    PubMed  CAS  Google Scholar 

  5. Centers for Disease Control and Prevention, American Society for Reproductive Medicine, RESOLVE: The National Infertility Association. 1998 Assisted Reproductive Technology Success Rates: National summary and fertility clinic reports. Vol. 1: http://www.cdc.gov/nccdphp/drh/art98/ PDF/art1998.pdf, 2000, p. 444.

    Google Scholar 

  6. Hurst T, Lancaster P. Assisted conception Australi and New Zealand 1999 and 2000. Sydney: Australian Institute of Health and Welfare National Perinatal Statistics Unit, 2001.

    Google Scholar 

  7. Nygren KG, Andersen AN. Assisted reproductive technology in Europe, 1997. Results generated from European registers by ESHRE. European IVF-Monitoring Programme (EIM), for the European Society of Human Reproduction and Embryology (ESHRE). Hum Reprod 2001; 16: 384–391.

    Google Scholar 

  8. O’Donovan PA, Vandekerckhove P, Lilford RJ, Hughes E. Treatment of male infertility: is it effective? Review and meta-analyses of published randomized controlled trials. Hum Reprod 1993; 8: 1209–1222.

    PubMed  Google Scholar 

  9. Vandekerckhove P, O’Donovan PA, Lilford RJ, Harada TW. Infertility treatment: from cookery to science. The epidemiology of randomised controlled trials. British J Ob Gyn 1993; 100: 1005–1036.

    Article  CAS  Google Scholar 

  10. Akre O, Cnattingius S, Bergstrom R, Kvist U, Trichopoulos D, Ekbom A Human fertility does not decline: evidence from Sweden. Fertil Steril 1999; 71: 1066–1069.

    Article  PubMed  CAS  Google Scholar 

  11. Anonymous. Multiple gestation pregnancy. The ESHRE Capri Workshop Group. Hum Reprod 2000; 15: 1856–1864.

    Google Scholar 

  12. Abramov Y, Elchalal U, Schenker JG. Severe OHSS: An `epidemic’ of severe OHSS: a price we have to pay? Hum Reprod 1999; 14: 2181–183.

    Article  PubMed  CAS  Google Scholar 

  13. Kurinczuk JJ, Bower C. Birth defects in infants conceived by intracytoplasmic sperm injection: an alternative interpretation. Br Med J 1997; 315: 1260–1265.

    Article  CAS  Google Scholar 

  14. Bowen JR, Gibson FL, Leslie GI, Saunders DM. Medical and developmental outcome at 1 year for children conceived by intracytoplasmic sperm injection. Lancet 1998; 351: 1529–1534.

    Article  PubMed  CAS  Google Scholar 

  15. Page DC, Silber S, Brown LG. Men with infertility caused by AZFc deletion can produce sons by intracytoplasmic sperm injection, but are likely to transmit the deletion and infertility. Hum Reprod 1999; 14: 1722–1726.

    Article  PubMed  CAS  Google Scholar 

  16. Foresta C, Moro E, Ferlin A. Y Chromosome Microdeletions and Alterations of Spermatogenesis. Endocr Rev 2001; 22: 226–239.

    Article  PubMed  CAS  Google Scholar 

  17. Schlegel PN, Su LM. Physiological consequences of testicular sperm extraction. Hum Reprod 1997; 12: 1688–1692.

    Article  PubMed  CAS  Google Scholar 

  18. Guzick DS, Overstreet JW, Factor-Litvak P, et al. Sperm morphology, motility, and concentration in fertile and infertile men. N Engl J Med 2001; 345: 1388–1393.

    Article  PubMed  CAS  Google Scholar 

  19. Polansky FF, Lamb EJ. Do the results of semen analysis predict future fertility? A survival analysis study. Fertil Steril 1988; 49: 1059–1065.

    PubMed  CAS  Google Scholar 

  20. Glazener CM, Kelly NJ, Weir MJ, David JS, Cornes JS, Hull MG. The diagnosis of male infertility-prospective time-specific study of conception rates related to seminal analysis and post-coital sperm-mucus penetration and survival in otherwise unexplained infertility. Hum Reprod 1987; 2: 665–671.

    PubMed  CAS  Google Scholar 

  21. Baker HWG. Male infertility. In: DeGroot LJ, Jameson JL, eds. Endocrinology, Vol. 3. Saunders, Philadelphia, 2001, 2308–2328.

    Google Scholar 

  22. Nachtigall LB, Boepple PA, Pralong FP, Crowley WF. Adult-onset idiopathic hypogonadotropic hypogonadism-a treatable form of male infertility. N Engl J Med 1997; 336: 410–415.

    Article  PubMed  CAS  Google Scholar 

  23. Seminara SB, Hayes FJ, Crowley WF, Jr. Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann’s syndrome): pathophysiological and genetic considerations. Endocr Rev 1998; 19: 521–539.

    Article  PubMed  CAS  Google Scholar 

  24. de Roux N, Young J, Brailly-Tabard S, Misrahi M, Milgrom E, Schaison G. The same molecular defects of the gonadotropin-releasing hormone receptor determine a variable degree of hypogonadism in affected kindred. J Clin Endocrinol Metab 1999; 84: 567–572.

    Article  PubMed  Google Scholar 

  25. Layman LC. Genetics of human hypogonadotropic hypogonadism. Am J Med Genet 1999; 89: 240–248.

    Article  PubMed  CAS  Google Scholar 

  26. Wang C, Tso SC, Todd D. Hypogonadotropic hypogonadism in severe beta-thalassemia: effect of chelation and pulsatile gonadotropin-releasing hormone therapy. J Clin Endocrinol Metab 1989; 68: 511–516.

    Article  PubMed  CAS  Google Scholar 

  27. Schaison G, Young J, Pholsena M, Nahoul K, Couzinet B. Failure of combined follicle-stimulating hormone-testosterone administration to initiate and/or maintain spermatogenesis in men with hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1993; 77: 1545–1549.

    Article  PubMed  CAS  Google Scholar 

  28. Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science 1978; 202: 631–633.

    Article  PubMed  CAS  Google Scholar 

  29. Crowley WF, Jr., Filicori M, Spratt DI, Santoro NF. The physiology of gonadotropin-releasing hormone (GnRH) secretion in men and women. Recent Prog Horm Res 1985; 41: 473–531.

    PubMed  CAS  Google Scholar 

  30. Handelsman DJ, Jansen RPS, Boylan LM, Spaliviero JA, Turtle JR. Pharmacokinetics of gonadotropin-releasing hormone: comparison of subcutaneous and intravenous routes. J Clin Endocrinol Metab 1984; 59: 739–46.

    Article  PubMed  CAS  Google Scholar 

  31. Liu L, Banks SM, Banres KM, Sherins RJ. Two year comparison of testicular responses to pulsatile gonadotropin-releasing hormone and exogenous gonadotropins from the inception of therapy in men with isolated hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1988; 67: 1140–1145.

    Article  PubMed  CAS  Google Scholar 

  32. Delemarre-Van de Waal HA. Induction of testicular growth and spermatogenesis by pulsatile, intravenous administration of gonadotrophin-releasing hormone in patients with hypogonadotrophic hypogonadism. Clin Endocrinol 1993; 38: 473–480.

    Google Scholar 

  33. Schopohl J, Mehltretter G, von Zumbusch R, Eversmann T, von Werder K. Comparison of gonadotropin-releasing hormone and gonadotropin therapy in male patients with idiopathic hypothalamic hypogonadism. Fertil Steril 1991; 56: 1143–1150.

    PubMed  CAS  Google Scholar 

  34. Buchter D, Behre HM, Kliesch S, Nieschlag E. Pulsatile GnRH or human chorionic gonadotropin/ human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. Eur J Endocrinol 1998; 139: 298–303.

    Article  PubMed  CAS  Google Scholar 

  35. Blumenfeld Z, Frisch L, Conn PM. Gonadotropin-releasing hormone (GnRH) antibodies formation in hypogonadotropic azoospermic men treated with pulsatile GnRH-diagnosis and possible alternative treatment. Fertil Steril 1988; 50: 622–629.

    PubMed  CAS  Google Scholar 

  36. Meakin JL, Keogh EJ, Martin CE. Human anti-luteinizing hormone-releasing hormone antibodies in patients treated with synthetic luteinizing hormone-releasing hormone. Fertil Steril 1985; 43: 811–813.

    PubMed  CAS  Google Scholar 

  37. Lindner J, McNeil LW, Marney S, et al. Characterization of human anti-luteinizing hormone-releasing hormone (LRH) antibodies in the serum of a patient with isolated gonadotropin deficiency treated with synthetic LRH. J Clin Endocrinol Metab 1981; 52: 267–270.

    Article  PubMed  CAS  Google Scholar 

  38. Gemzell C, Kjessler B. Treatment of infertility arter partial hypophysectomy with human gonadotrophins. Lancet 1964; 1: 644.

    Article  PubMed  CAS  Google Scholar 

  39. Burger HG, Baker HWG. Therapeutic considerations and results of gonadotropin treatment in male hypogonadotropic hypogonadism. Ann NY Acad Sci 1984; 438: 447–453.

    Article  PubMed  CAS  Google Scholar 

  40. Liu PY, Turner L, Rushford D, et al. Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men. Hum Reprod 1999; 14: 1540–1545.

    Article  PubMed  CAS  Google Scholar 

  41. Cochius JI, Burns RJ, Blumbergs PC, Mack K, Alderman CP. Creutzfeldt-Jakob disease in a recipient of human pituitary-derived gonadotrophin. Aust NZ J Med 1990; 20: 592, 593.

    Google Scholar 

  42. Healy DL, Evans J. Creutzfeldt-Jakob disease after pituitary gonadotrophins. Br MedJ 1993; 307: 517, 518.

    Google Scholar 

  43. Liu PY, Gebski VJ, Turner L, Conway AJ, Wishart SM, Handelsman DJ. Predicting pregnancy and spermatogenesis by survival analysis during gonadotropin treatment of gonadotropin deficient infertile men. Hum Reprod 2002: 17: 625–633.

    Article  PubMed  Google Scholar 

  44. Vicari E, Mongioi A, Calogero AE, et al. Therapy with human chorionic gonadotrophin alone induces spermatogenesis in men with isolated hypogonadotrophic hypogonadism-long-term follow-up. Int J Androl 1992; 15: 320–329.

    Article  PubMed  CAS  Google Scholar 

  45. Anonymous. Efficacy and safety of highly purified urinary follicle-stimulating hormone with human chorionic gonadotropin for treating men with isolated hypogonadotropic hypogonadism. European Metrodin HP Study Group. Fertil Steril 1998; 70: 256–262.

    Article  Google Scholar 

  46. Burgues S, Calderon MD. Subcutaneous self-administration of highly purified follicle stimulating hormone and human chorionic gonadotrophin for the treatment of male hypogonadotrophic hypogonadism. Spanish Collaborative Group on Male Hypogonadotropic Hypogonadism. Hum Reprod 1997; 12: 980–986.

    Article  PubMed  CAS  Google Scholar 

  47. Kung AW, Zhong YY, Lam KS, Wang C. Induction of spermatogenesis with gonadotrophins in Chinese men with hypogonadotrophic hypogonadism. Int J Androl 1994; 17: 241–247.

    Article  PubMed  CAS  Google Scholar 

  48. Kirk JMW, Savage MO, Grant DB, Bouloux PMG, Besser GM. Gonadal function and response to human chorionic and menopausal gonadotrophin therapy in male patients with idiopathic hypogonadotrophic hypogonadism. Clin Endocrinol 1994; 41: 57–63.

    Article  CAS  Google Scholar 

  49. Okada Y, Kondo T, Okamoto S, Ogawa M. Induction of ovulation and spermatogenesis by hMG/ hCG in hypogonadotropic GH-deficient patients. Endocrinologia Japonica 1992; 39: 31–43.

    Article  PubMed  CAS  Google Scholar 

  50. Saal W, Happ J, Cordes U, Baum RP, Schmidt M. Subcutaneous gonadotropin therapy in male patients with hypogonadotropic hypogonadism. Fertil Steril 1991; 56: 319–324.

    PubMed  CAS  Google Scholar 

  51. Mastrogiacomo I, Motta RG, Botteon S, Bonanni G, Schiesaro M. Achievement of spermatogenesis and genital tract maturation in hypogonadotropic hypogonadic subjects during long term treatment with gonadotropins or LHRH. Andrologia 1991; 23: 285–289.

    Article  PubMed  CAS  Google Scholar 

  52. Burris AS, Rodbard HW, Winters SJ, Sherins RJ. Gonadotropin therapy in men with isolated hypogonadotropic hypogonadism: the response to human chorionic gonadotropin is predicted by initial testicular size. J Clin Endocrinol Metab 1988; 66: 1144–1151.

    Article  PubMed  CAS  Google Scholar 

  53. Okuyama A, Nakamura M, Namiki M, et al. Testicular responsiveness to long-term administration of hCG and hMG in patients with hypogonadotrophic hypogonadism. Hormone Res 1986; 23: 21–30.

    Article  PubMed  CAS  Google Scholar 

  54. Finkel DM, Phillips JL, Snyder N. Stimulation of spermatogenesis by gonadotropins in men with hypogonadotropic hypogonadism. N Engl J Med 1985; 313: 651–655.

    Article  PubMed  CAS  Google Scholar 

  55. Barrio R, de Luis D, Alonso M, Lamas A, Moreno JC. Induction of puberty with human chorionic gonadotropin and follicle-stimulating hormone in adolescent males with hypogonadotropic hypogonadism. Fertil Steril 1999; 71: 244–248.

    Article  PubMed  CAS  Google Scholar 

  56. Bouvattier C, Tauber M, Jouret B, Chaussain JL, Rochiccioli P. Gonadotropin treatment of hypogonadotropic hypogonadal adolescents. J Ped Endocrinol Metab 1999; 12: 339–344.

    Google Scholar 

  57. Tachiki H, Ito N, Maruta H, Kumamoto Y, Tsukamoto T. Testicular findings, endocrine features and therapeutic responses of men with acquired hypogonadotropic hypogonadism Int J Urol 1998; 5: 80–85.

    CAS  Google Scholar 

  58. Kliesch S, Behre HM, Nieschlag E. High efficacy of gonadotrophin or pusatile gonadotrophin-releasing hormone treatment in hypogonadotrophic hypogonadal men. Eur J Endocrinol 1994; 131: 347–354.

    Article  PubMed  CAS  Google Scholar 

  59. Jones TH, Darne JF. Self-administered subcutaneous human menopausal gonadotrophin for stimulation of testicular growth and the initiation of spermatogenesis in hypogonadotropic hypogonadism. Clin Endocrinol 1993; 38: 203–208.

    Article  CAS  Google Scholar 

  60. Ley SB, Leonard JM. Male hypogonadotropic hypogonadism: factors influencing response to human chorionic gonadotropin and human menopausal gonadotropin, including prior exogenous androgens. J Clin Endocrinol Metab 1985; 61: 746–752.

    Article  PubMed  CAS  Google Scholar 

  61. Hull KL, Harvey S. Growth hormone: a reproductive endocrine-paracrine regulator? Rev Reprod 2000; 5: 175–182.

    Article  PubMed  CAS  Google Scholar 

  62. Carani C, Granata AR, De Rosa M, et al. The effect of chronic treatment with GH on gonadal function in men with isolated GH deficiency. Eur J Endocrinol 1999; 140: 224–230.

    Article  PubMed  CAS  Google Scholar 

  63. Zalel Y, Draysen E, Goldschmit R, Zadik Z, Shoham Z. A prospective pilot study of co-treatment with growth hormone and gonadotropins for improving spermatogenesis in normogonadotropic patients with severe oligoteratoasthenospermia. Gyn Endocrinol 1996; 10: 23–28.

    Article  CAS  Google Scholar 

  64. Zalel Y, Manor M, Zadik Z, Shoham Z. Successful induction of spermatogenesis in a patient with hypogonadotropic hypogonadism following co-treatment with growth hormone. Gyn Endocrinol 1996; 10: 29–31.

    Article  CAS  Google Scholar 

  65. Lee KO, Ng SC, Lee PS, et al. Effect of growth hormone therapy in men with severe idiopathic oligozoospermia. Eur J Endocrinol 1995; 132: 159–162.

    Article  PubMed  CAS  Google Scholar 

  66. Radicioni A, Paris E, Dondero F, Bonifacio V, Isidori A. Recombinant-growth hormone (rec-hGH) therapy in infertile men with idiopathic oligozoospermia. Acta Europaea Fertilitatis 1994; 25: 311–317.

    PubMed  CAS  Google Scholar 

  67. Shoham Z, Conway GS, Ostergaard H, Lahlou N, Bouchard P, Jacobs HS. Cotreatment with growth hormone for induction of spermatogenesis in patients with hypogonadotropic hypogonadism. Fertil Steril 1992; 57: 1044–1051.

    PubMed  CAS  Google Scholar 

  68. Crawford BA, Handelsman DJ. Recombinant growth hormone and insulin-like growth factor I do not alter gonadotrophin stimulation of the baboon testis in vivo. Eur J Endocrinol 1994; 131: 405–412.

    Article  PubMed  CAS  Google Scholar 

  69. Abshagen K, Behre HM, Cooper TG, Nieschlag E. Influence of sperm surface antibodies on spontaneous pregnancy rates. Fertil Steril 1998; 70: 355, 356.

    Google Scholar 

  70. Clarke GN, Bourne H, Baker HW. Intracytoplasmic sperm injection for treating infertility associated with sperm autoimmunity. Fertil Steril 1997; 68: 112–117.

    Article  PubMed  CAS  Google Scholar 

  71. Grigoriou O, Konidaris S, Antonaki V, Papadias C, Antoniou G, Gargaropoulos A. Corticosteroid treatment does not improve the results of intrauterine insemination in male subfertility caused by antisperm antibodies. Eur J Ob Gyn Reprod Biol 1996; 65: 227–230.

    Article  CAS  Google Scholar 

  72. Omu AE, al-Qattan F, Abdul Hamada B. Effect of low dose continuous corticosteroid therapy in men with antisperm antibodies on spermatozoal quality and conception rate. Eur J Ob Gyn Reprod Biol 1996; 69: 129–134.

    Article  CAS  Google Scholar 

  73. Lahteenmaki A, Rasanen M, Hovatta O. Low-dose prednisolone does not improve the outcome of in-vitro fertilization in male immunological infertility. Hum Reprod 1995; 10: 3124–3129.

    Article  PubMed  CAS  Google Scholar 

  74. Bals-Pratsch M, Doren M, Karbowski B, Schneider HP, Nieschlag E. Cyclic corticosteroid immunosuppression is unsuccessful in the treatment of sperm antibody-related male infertility: a controlled study. Hum Reprod 1992; 7: 99–104.

    PubMed  CAS  Google Scholar 

  75. Hendry WF, Hughes L, Scammell G, Pryor JP, Hargreave TB. Comparison of prednisolone and placebo in subfertile men with antibodies to spermatozoa. Lancet 1990; 335: 85–88.

    Article  PubMed  CAS  Google Scholar 

  76. Haas GG, Jr., Manganiello P. A double-blind, placebo-controlled study of the use of methylprednisolone in infertile men with sperm-associated immunoglobulins. Fertil Steril 1987; 47: 295–301.

    PubMed  Google Scholar 

  77. Kamischke A, Nieschlag E. Analysis of medical treatment of male infertility. Hum Reprod 1999; 14: 1–23.

    Article  PubMed  Google Scholar 

  78. Badenoch DF, Waxman J, Boorman L, et al. Administration of a gonadotropin releasing hormone analogue in oligozoospermic infertile males. Acta Endocrinologica 1988; 117: 265–267.

    PubMed  CAS  Google Scholar 

  79. Matorras R, Perez C, Corcostegui B, et al. Treatment of the male with follicle-stimulating hormone in intrauterine insemination with husband’s spermatozoa: a randomized study. Hum Reprod 1997; 12: 24–28.

    Article  PubMed  CAS  Google Scholar 

  80. Kamischke A, Behre HM, Bergmann M, Simoni M, Schafer T, Nieschlag E. Recombinant human follicle stimulating hormone for treatment of male idiopathic infertility: a randomized, double-blind, placebo-controlled, clinical trial. Hum Reprod 1998; 13: 596–603.

    Article  PubMed  CAS  Google Scholar 

  81. Ashkenazi J, Bar-Hava I, Farhi J, et al. The role of purified follicle stimulating hormone therapy in the male partner before intracytoplasmic sperm injection. Fertil Steril 1999; 72: 670–673.

    Article  PubMed  CAS  Google Scholar 

  82. Knuth UA, Honigl W, Bals-Pratsch M, Schleicher G, Nieschlag E. Treatment of severe oligospermia with human chorionic gonadotropin/human menopausal gonadotropin: a placebo-controlled, double blind trial. J Clin Endocrinol Metab 1987; 65: 1081–1087.

    Article  PubMed  CAS  Google Scholar 

  83. Schill WB, Haidl G. Medical treatment of male infertility. In: Insler V, Lunenfeld B, eds. Infertility: Male and Female. Churchill Livingstone, New York, 1993, pp. 575–622.

    Google Scholar 

  84. Aafjes JH, van der Vijver JC, Brugman FW, Schenck PE. Double-blind cross over treatment with mesterolone and placebo of subfertile oligozoospermic men value of testicular biopsy. Andrologia 1983; 15: 531–535.

    Article  PubMed  Google Scholar 

  85. Anonymous. Mesterolone and idiopathic male infertility: a double-blind study. World Health Organization Task Force on the Diagnosis and Treatment of Infertility. Int J Androl 1989; 12: 254–264.

    Article  Google Scholar 

  86. Comhaire F, Schoonjans F, Abdelmassih R, et al. Does treatment with testosterone undecanoate improve the in-vitro fertilizing capacity of spermatozoa in patients with idiopathic testicular failure? (results of a double blind study). Hum Reprod 1995; 10: 2600–2602.

    PubMed  CAS  Google Scholar 

  87. Comhaire F. Treatment of idiopathic testicular failure with high-dose testosterone undecanoate: a double-blind pilot study. Fertil Steril 1990; 54: 689–693.

    PubMed  CAS  Google Scholar 

  88. Gerris J, Comhaire F, Hellemans P, Peeters K, Schoonjans F. Placebo-controlled trial of high-dose Mesterolone treatment of idiopathic male infertility. Fertil Steril 1991; 55: 603–607.

    PubMed  CAS  Google Scholar 

  89. Gregoriou O, Papadias C, Gargaropoulos A, Konidaris S, Kontogeorgi Z, Kalampokas E. Treatment of idiopathic infertility with testosterone undecanoate. A double blind study. Clin Exp Ob Gyn 1993; 20: 9–12.

    CAS  Google Scholar 

  90. Hargreave TB, Kyle KF, Baxby K, et al. Randomised trial of mesterolone versus vitamin C for male infertility. Scottish Infertility Group. Br J Urol 1984; 56: 740–744.

    Article  PubMed  CAS  Google Scholar 

  91. Mauss J. Results of treatment of male fertility disorders with mesterolone or a placebo. Arzneimittel-Forschung 1974; 24: 1338–1341.

    PubMed  CAS  Google Scholar 

  92. Pusch HH. Oral treatment of oligozoospermia with testosterone-undecanoate: results of a doubleblind-placebo-controlled trial. Andrologia 1989; 21: 76–82.

    Article  PubMed  CAS  Google Scholar 

  93. Wang C, Chan CW, Wong KK, Yeung KK. Comparison of the effectiveness of placebo, clomiphene citrate, mesterolone, pentoxifylline, and testosterone rebound therapy for the treatment of idiopathic oligospermia. Fertil Steril 1983; 40: 358–365.

    PubMed  CAS  Google Scholar 

  94. Vandekerckhove P, Lilford R, Vail A, Hughes E. Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia (Cochrane Review). Cochrane Database of Systematic Reviews, vol. 3. Update Software, Oxford, 2001.

    Google Scholar 

  95. Ronnberg L. The effect of clomiphene citrate on different sperm parameters and serum hormone levels in preselected infertile men: a controlled double-blind cross-over study. Int J Androl 1980; 3: 479–486.

    Article  PubMed  CAS  Google Scholar 

  96. Abel BJ, Carswell G, Elton R, et al. Randomised trial of clomiphene citrate treatment and vitamin C for male infertility. Br J Urol 1982; 54: 780–784.

    Article  PubMed  CAS  Google Scholar 

  97. Torok L. Treatment of oligozoospermia with tamoxifen (open and controlled studies). Andrologia 1985; 17: 497–501.

    Article  PubMed  CAS  Google Scholar 

  98. Micic S, Dotlic R. Evaluation of sperm parameters in clinical trial with clomiphene citrate of oligospermic men. J Urol 1985; 133: 221, 222.

    Google Scholar 

  99. Hargreave T, Sweeting V, Elton R. Randomised trial of tamoxifen versus vitamin C for male infertility. In: Ratman S, Teoh E, Anandaukmar, eds. Advances in Fertility and Sterility Series: Infertility, Male and Female. vol. 4, Partenon Publishing Group, 1986, pp. 51–57.

    Google Scholar 

  100. AinMelk Y, Belisle S, Carmel M, Jean-Pierre T. Tamoxifen citrate therapy in male infertility. Fertil Steril 1987; 48: 113–117.

    PubMed  CAS  Google Scholar 

  101. Sokol RZ, Steiner BS, Bustillo M, Petersen G, Swerdloff RS. A controlled comparison of the efficacy of clomiphene citrate in male infertility. Fertil Steril 1988; 49: 865–870.

    PubMed  CAS  Google Scholar 

  102. Krause W, Holland-Moritz H, Schramm P. Treatment of idiopathic oligozoospermia with tamoxifen-a randomized controlled study. Int J Androl 1992; 15: 14–18.

    Article  PubMed  CAS  Google Scholar 

  103. Anonymous. A double-blind trial of clomiphene citrate for the treatment of idiopathic male infertility. World Health Organization. Int J Androl 1992; 15: 299–307.

    Google Scholar 

  104. Vandekerckhove P, Lilford R, Vail A, Hughes E. Clomiphene or tamoxifen for idiopathic oligo/ asthenospermia (Cochrane Review). Cochrane Database of Systematic Reviews, vol. 3. Update Software, Oxford, 2001: p. 3.

    Google Scholar 

  105. Clark RV, Sherins RJ. Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactone. Results of a double-blinded, randomized, placebo-controlled trial with crossover. J Androl 1989; 10: 240–247.

    PubMed  CAS  Google Scholar 

  106. Pavlovich CP, King P, Goldstein M, Schlegel PN. Evidence of a treatable endocrinopathy in infertile men. J Urol 2001; 165: 837–841.

    Article  PubMed  CAS  Google Scholar 

  107. O’Donnell L, Robertson KM, Jones ME, Simpson ER. Estrogen and spermatogenesis. Endocr Rev 2001; 22: 289–318.

    Article  PubMed  Google Scholar 

  108. Grumbach MM. Estrogen, bone, growth and sex: a sea change in conventional wisdom. J Ped Endocrinol Metab 2000; 13: 1439–1455.

    Google Scholar 

  109. Carter JN, Tyson JE, Tolis G, Van Vliet S, Faiman C, Friesen HG. Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med 1978; 299: 847–852.

    Article  PubMed  CAS  Google Scholar 

  110. Lunglmayr G, Maier U, Spona J. Therapie der idiopathischen Oligozoospermie mit Bromokriptin Resultate einer prospektiv kontrollierten Studie. Andrologia 1983; 15: 548–553.

    Article  PubMed  Google Scholar 

  111. AinMelk Y, Belisle S, Kandalaft N, McClure D, Tetreault L, Elhilali M. Bromocriptine therapy in oligozoospermic infertile men. Arch Androl 1982; 8: 135–141.

    Article  PubMed  CAS  Google Scholar 

  112. Hovatta O, Koskimies AI, Ranta T, Stenman UH, Seppala M. Bromocriptine treatment of oligospermia: a double blind study. Clin Endocrinol 1979; 11: 377–382.

    Article  CAS  Google Scholar 

  113. Vandekerckhove P, Lilford R, Vail A, Hughes E. Bromocriptine for idiopathic oligo/asthenospermia (Cochrane Review). Cochrane Database of Systematic Reviews, vol. 3. Update Software, Oxford, 2001, pp. 3.

    Google Scholar 

  114. Morris ID. Protection against cytotoxic-induced testis damage–experimental approaches. Eur Urol 1993; 23: 143–147.

    PubMed  CAS  Google Scholar 

  115. Chemes HE. Infancy is not a quiescent period of testicular development. Int J Androl 2001; 24: 2–7.

    Article  PubMed  CAS  Google Scholar 

  116. Shalet SM, Beardwell CG, Jacobs HS, Pearson D. Testicular function following irradiation of the human prepubertal testis. Clin Endocrinol 1978; 9: 483–490.

    Article  CAS  Google Scholar 

  117. Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotrophin-releasing hormone. Lancet 1981; 1: 1132–1134.

    Article  PubMed  CAS  Google Scholar 

  118. da Cunha MF, Meistrich ML, Nader S. Absence of protection by a GnRH analogue against cyclophosphamide induced testicular cytotoxicity in the mouse. Cancer Res 1987; 47: 1093–1097.

    PubMed  Google Scholar 

  119. Bex FJ, Corbin A, France E. Resistance of the mouse to the antifertility effects of LHRH agonists. Life Sci 1982; 30: 1263–1269.

    Article  PubMed  CAS  Google Scholar 

  120. Waxman JH, Ahmed R, Smith D, et al. Failure to preserve fertility in patients with Hodgkin’ s disease. Cancer Chemo Pharmacol 1987; 19: 159–162.

    Article  CAS  Google Scholar 

  121. Kreusser ED, Hetzel WD, Hautmann R, Pfeiffer EF. Reproductive toxicity with and without LHRHa administration during adjuvant chemotherapy in patients with germ cell tumors. Hormone Metab Res 1990; 22: 494–498.

    Article  Google Scholar 

  122. Brennemann W, Brensing KA, Leipner N, Boldt I, Klingmuller D. Attempted protection of spermatogenesis from irradiation in patients with seminoma by D-Tryptophan-6 luteinizing hormone releasing hormone. Clin Invest 1994; 72: 838–842.

    Article  CAS  Google Scholar 

  123. Johnson DH, Linde R, Hainsworth JD, et al. Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on post-therapy fertility in male patients with lymphoma: preliminary observations. Blood 1985; 65: 832–836.

    PubMed  CAS  Google Scholar 

  124. Masala A, Faedda R, Alagna A, et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Int Med 1997; 126: 292–295.

    PubMed  CAS  Google Scholar 

  125. Kelleher S, Wishart SM, Liu PY, et al. Long-term outcomes of elective human sperm cryostorage. Hum Reprod 2001; 16: 2632–2639.

    Article  PubMed  CAS  Google Scholar 

  126. Schlatt S, von Schonfeldt V, Schepers AG. Male germ cell transplantation: an experimental approach with a clinical perspective. Br Med Bull 2000; 56: 824–836.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Peter Y. Liu MBBS, FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J. Handelsman MBBS, FRACP, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine and Pathology, University of Utah School of Medicine and ARUP Laboratory, Salt Lake City, UT, USA

    A. Wayne Meikle MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Liu, P.Y., Handelsman, D.J. (2003). Hormonal Therapy of the Infertile Man. In: Meikle, A.W. (eds) Endocrine Replacement Therapy in Clinical Practice. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-375-0_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-375-0_24

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-416-6

  • Online ISBN: 978-1-59259-375-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation